Form 8-K - Current report:
SEC Accession No. 0001213900-25-018135
Filing Date
2025-02-27
Accepted
2025-02-27 17:00:43
Documents
15
Period of Report
2025-02-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0232360-8k_oramed.htm   iXBRL 8-K 36392
2 LICENSE AGREEMENT (ZTLIDO), DATED FEBRUARY 22, 2025, BY AND BETWEEN SCILEX PHARM ea023236001ex10-1_oramed.htm EX-10.1 348429
3 PARENT GUARANTEE FOR LIDOCAINE LICENSE AGREEMENT, DATED FEBRUARY 22, 2025, BY AN ea023236001ex10-2_oramed.htm EX-10.2 32746
  Complete submission text file 0001213900-25-018135.txt   664693

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ormp-20250222.xsd EX-101.SCH 3009
5 XBRL LABEL FILE ormp-20250222_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE ormp-20250222_pre.xml EX-101.PRE 22355
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0232360-8k_oramed_htm.xml XML 3807
Mailing Address 1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK NY 10036
Business Address 1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK NY 10036 646-844-1164
ORAMED PHARMACEUTICALS INC. (Filer) CIK: 0001176309 (see all company filings)

EIN.: 980376008 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35813 | Film No.: 25680431
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)